Expert Guidance on the Management of Ulcerative Colitis

Enter patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.

Anita Afzali, MD, MPH, MHCM, FACG, AGAF Adam Cheifetz, MD Raymond K. Cross, MD, MS Millie D. Long, MD, MPH, FACG, AGAF David A. Schwartz, MD, FACG, AGAF Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: October 28, 2020 Expired: No longer available for credit

In this interactive virtual presentation, 2 experts discuss assessing disease risk and individualizing treatment for patients with moderate to severe UC.

Anita Afzali, MD, MPH, MHCM, FACG, AGAF Millie D. Long, MD, MPH, FACG, AGAF Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: November 13, 2020 Expired: No longer available for credit

Introduction

Moderate to Severe UC

Why TNF Inhibitors?

Beyond TNF Inhibitors

Safety

Individualizing Treatment

Summary

Learn how to assess disease risk and individualize treatment for patients with moderate to severe UC.

We now have more effective and safe therapeutic options than ever. But which medicine is optimal for a given patient, and how do we choose?

Raymond K. Cross, MD, MS Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: December 14, 2020 Expired: No longer available for credit